For 50 years the emphasis of obstetric management has shifted from the mother to the unborn child. Maternal mortality has fallen from rates of 4 per 1000 or greater to rates of 0-2 per 1000, so that the chances of a woman dying during pregnancy are hardly more than those if she were not pregnant over the same time period (Registrar General, 1972) . But perinatal mortality at around 25 per 1000 continues to be well above the possible minimum; furthermore there will be two or three children severely damaged for every one which dies (Chard, 1974a) . The prevention of perinatal mortality and morbidity might, in part, be achieved by intensification of the existing clinical approach. Yet the scope of purely clinical methods has probably reached its peak, and most advances are certain to involve laboratory-orientated technology, including electronic and biochemical methods for the assessment of fetal wellbeing and growth.
With the exception of congenital abnormality, the placenta is the common denominator in many of the conditions which threaten fetal wellbeing. For the whole period of intrauterine life, the placenta has to act as lung, gut, kidney, and as a barrier to infection. Most of the biochemical methods are directed towards the study of this organ and its relationship with the fetus.
Fetoplacental Synthetic Functions
The main function of the placenta is the transfer of nutrients and waste products between the mother and fetus. A test that measured this function would be of immense clinical value; attempts to develop the appropriate technology have so far not been generally applied (Garrow and Douglas, 1968; Chatfield et al, 1975) . As an alternative, therefore, most current methods are tests of placental synthesis.
The placenta produces an extensive range of substances, including enzymes and hormones, which differ either qualitatively or quantitatively from those in the non-pregnant adult ( (fig 1) . Certain parts of the trophoblast may be more active than others and there is evidence for specialization into thin areas adjacent to fetal capillaries, which are responsible for transport, and thicker areas, not adjacent to capillaries, which are responsible for synthesis (Burgos and Rodriguez, 1966 (from Chard, 1974b) .
Fetal Liver
The concentration of fetoplacental products in the mother will vary with the amount produced, and also with maternal metabolism and excretion. It might be anticipated that the product of a given fetoplacental unit would give half the circulating level in a 12-stone woman as it would be in a 6-stone woman. Body weight is rarely considered in the interpretation of hormonal tests of placental function, though it might be of considerable practical significance. Furthermore, it is often not realized that the excretion of oestrogen conjugates in urine is dependent on urine flow rate: the total excretion in 24 hours is greater if the patient excretes 2 litres rather than 1 litre of urine. In addition, the rate of excretion in urine can vary with renal function: low urine oestrogens in a patient with preeclampsia may reflect the associated renal lesion as well as fetoplacental dysfunction.
The control mechanisms for the production of specific placental products are virtually unknown. In adult life the release of hormones is characterized by well defined feedback systems on which are based several dynamic tests of function. In the placenta such factors are much less obvious. Thus, though HPL probably plays a role in carbohydrate and lipid metabolism, there is only a minimal response to intravenous glucose (Pavlou et al, 1973) . Trophoblastic synthesis of hormones seems to be virtually autonomous, in a manner similar to that of some adult tumours, though it can be changed by an alteration in the supply of precursors; for instance, oestriol synthesis is reduced in association with corticosteroid therapy (Oakey, 1970) due to suppression of the fetal pituitaryadrenal axis and a decrease in the synthesis of DHA (fig 1) . Production of placental hormones may also be influenced by the rate of blood flow in the intervillous space (McNeilly et al, 1976);  this is particularly important in considering the mechanism of reduced levels in pathological pregnancies.
The functional significance of most placental hormones is doubtful. On many occasions it has been suggested that the placental steroids play an important part in the maintenance of pregnancy and the onset of spontaneous labour (see Klopper and Gardner, 1974) , but the nature of the precise action is as yet uncertain. It has also been suggested that the specific hormones of the placenta are responsible for the metabolic alterations observed in the mother during pregnancy. It is difficult to attribute a specific change to a specific hormone: thus changes in carbohydrate and lipid metabolism may be due to many factors, both steroid and protein, and no one hormone can be pointed out as preeminent.
The Clinical Evaluation of Biochemical Tests of Fetoplacental Function
Much effort is spent on the identification of new parameters of fetoplacental function when, in fact, the main requirement is for detailed evaluation and refinement of tests which are already available. Probably most of the substances shown in table I would be an effective index of fetoplacental wellbeing, but the convenience and precision of measurement is probably more important than the nature of the material.
The practical use of tests of fetoplacental function has been retarded rather than advanced by much of the published information. The literature consists, with some notable exceptions, of case reports which are of little value to the obstetrician because they do not reflect the bulk of day-to-day clinical practice. Cases are often presented in which striking clinical events are associated with equally dramatic bio-chemical changes, yet often laboratory investigations have played little part in the practical management of these patients. Three criteria should be fulfilled if fetoplacental hormone determinations are to be useful in clinical practice: the definition of a normal range, the definition of the range for abnormalities and its relation to fetal outcome, and the interpretation of results from an individual subject related to the range of normal and abnormal.
NORMAL RANGE
A normal range for a fetoplacental product should be based on sufficient numbers of subjects and samples (at least 100 for each week of pregnancy), and the criteria for a normal pregnancy should be clearly defined. The optimal presentation of the range is as a mean, plus and minus two standard deviations; this is easily understood by the clinician and is comparable from one group of workers to the next. It is important to realize that, with most tests, the range is not normally distributed, but, instead, is skewed at the upper end by the occurrence of a few relatively high values (fig 2) . Thus, the mean and the range should be calculated either as centiles or after logarithmic or square root transformation of the data. The resultant range shows less variance below the mean than above it, and it is in the former that most values of clinical interest will lie.
The variance of the normal range reflects on the potential clinical use of a test. Where normal variation is considerable, substantial overlap with the abnormal is likely and the test is unlikely to be of value. The variation observed has two parts: one due to the biological differences between individuals, and the other to errors in the method of estimation (fig 3) . Variations due to biological spread can only be reduced by subdividing the population into clinically recognizable groups, but assay variation can be improved by detailed attention to laboratory procedure and sample collection. A unit setting up a test for the first time should always establish its own normal range, since even with well established methodology small variations in the population examined can yield ranges which differ strikingly from those presented by other groups.
THE RANGE IN ABNORMALITIES
The aim of a laboratory test is to give information on the wellbeing of a pregnancy which cannot be obtained by clinical means. Tests relating to the maternal disease are helpful only if they provide evidence that enables the clinician to assess fetal prognosis. It is important to consider both the normal range and the range for the abnormality. A good example is provided by the study of HPL levels in diabetic pregnancy (Ursell et al, 1973 Chard, 1974b or below these limits. Using this approach it is often found that the accumulation of small risk factors, eg, levels of placental hormones at the lower end of the normal range (fig 6) , may together create a situation of high risk which demands immediate attention from the obstetrician. It must be appreciated that a biochemical measurement is no more definite than, for instance, measurement of blood pressure; this has, in the past, produced disillusion with techniques which were over-enthusiastically introduced.
The charting of serial levels in individual patients is important since high risk may be indicated by a progressive fall. However, this is a rare event in practice and when it is observed, it is important to exclude the possibility that it reflects random variations of the method or the patient. A considerably more important function of serial levels is the added confidence that they give to the relationship between individual results and those of the whole population. A series of values at the lower limit of normal may suggest a greater risk than one isolated value which is far lower. (Leek et al, 1975 (Gold and Freedman, 1965) . High concend in terms of substrate activity rather than trations are found in the fetus and small amounts in such activity can measure a heterogeneous maternal blood. Measurement is by radioimmunoassay.
)d of measurement should be rapid, simple, and precise.
The only clinical application has been the estimalife in the mother should be short so that any change in tion of CEA in amniotic fluid as a guide to fetal tion is rapidly reflected in the concentration in blood or distress (Goldenberg et al, 1972 ). The concept is that dhan and day-to-day variation should be minimal. Table II ( offetoplace -------I FETOPLACENTAL STEROID HORMONES Progesterone Some 15% of the progesterone synthesized by the placenta is excreted in maternal urine as pregnanediol. Determination of this has been used as a test of placental function, but the measurement is timeconsuming and this, together with the problems of sample collection, explains the limited published evidence on this subject.
Chemical determination of pregnanediol in urine is likely to be replaced by direct radioimmunoassay of progesterone in blood. There is as yet no substantial literature on the clinical application of this technique, though the significance of blood progesterone values is likely to be similar to that of placental lactogen (see below).
Oestrogens
Oestriol is quantitatively the most important of the major oestrogens in late pregnancy. It is synthesized by the placenta from fetal precursors (fig 1) and thus reflects the function of both fetus and placenta together rather than, aswith othermaterials, the function of the placenta alone (Diczfalusy and Mancuso, 1969; Beling, 1971 ).
Most work on oestrogens has, until recently, been based on determination in a 24-hour specimen of urine. This has the great disadvantage that the collection is often inaccurate. Measurement of oestriol in maternal blood is increasingly widely used and may well replace the use of urinary oestriol in obstetric practice. This has been made possible by the introduction of radioimmunoassay which is sufficiently sensitive to permit precise estimation of the relatively low circulating levels.
Most of the published evidence on the clinical use of oestrogen measurement concerns the urinary oestrogens. A typical range of normal values is shown in figure 7 ; this range will vary in different laboratories, and every group should establish their own normal values. Low or subnormal oestrogen values reflect an increased risk to the fetus in several of the common complications of pregnancy, including intrauterine growth retardation (Yousem et al, 1966; Heys et al, 1968) , preeclampsia (Macleod et al, 1967; Bj0ro, 1972) , and diabetes mellitus (Evans et al, 1972) . In prolonged pregnancy, subnormal or decreasing levels are an indication for immediate delivery (Smith et al, 1966; Lundvall and Stakemann, 1966; Beischer et al, 1969) . Urinary oestriol levels are low in most cases of fetal death (Frandsen and Stakemann, 1960; Heys et al, 1968 measurement is in the prediction of fetal risk in an apparently normal pregnancy (Beischer et al, 1968) .
The use of biochemical procedures as screening tests is further discussed below.
Information on the clinical use of blood oestrogen determination is still relatively sparse. In addition, it is still not certain which oestrogen fraction should be measured: the principal candidates are unconjugated oestriol and total oestriol (conjugated and unconjugated) (see Klopper and Shaaban, 1973 (Brody, 1969) .
Human placental lactogen Human placental lactogen (HPL) is a specific placental protein which is immunologically and chemically similar to pituitary growth hormone and prolactin. Levels in maternal blood rise progressively during pregnancy reaching a plateau after the 35th week (fig 8) . The measurement of HPL by radioimmunoassay is simple, rapid and precise, and is increasingly widely used in the diagnosis of complications in both late and early pregnancy (see Chard, 1975) . The normal range of HPL levels in maternal blood (fig 8) is less wide than that of either urine or plasma oestrogens. Low normal or subnormal concentrations reflect increased fetal risk in complications such as threatened abortion (Niven et al, 1973) , T. Chard preeclampsia (Spellacy et al, 1971; Keller et al, 1971; Lindberg and Nilsson, 1973) , and diabetes mellitus (Ursell et al, 1973 ) (see also figs 4 and 5). HPL levels are related to fetal weight, but they are less efficient in the identification of intrauterine growth retardation than the fetus-dependent oestrogens. The levels are often low before fetal death (Spellacy et al, 1971; Ward et al, 1973) . In rhesus isoimmunization, high levels of HPL before the 26th week of pregnancy suggest that the condition is likely to be severe (Ward et al, 1974) . Low levels of HPL may predict fetal complications in the apparent absence of clinical abnormality England et al, 1974 ); values of less than 4 ,ug/ml after the 35th week are associated with a high incidence of fetal distress during labour and neonatal asphyxia after delivery.
Other placental protein hormones (table I) have not been examined as tests of fetal welfare. It seems likely that their significance would be similar to that of HPL.
DYNAMIC TESTS OF PLACENTAL HORMONE SYNTHESIS
The administration of dehydroepiandrosterone sulphate (DHA) to the mother leads to an increase in placental oestrogen synthesis (Lauritzen, 1967 ) (see fig 3) . This procedure might provide a test of placental reserve capacity but considerably more work is needed before it can be used in practice. 
Conclusions

